FDA Brief

Warning letters Drugs

FDA warning letter to

Zhejiang Qimei Cosmetics Co., Ltd.

High riskIssued Nov 7, 2024Posted Nov 12, 2024Center for Drug Evaluation and Research (CDER)

Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.

What happened

FDA reviewed records the company submitted after its March 11, 2024 request under section 704(a)(4) of the FD&C Act. FDA found the quality unit did not show the sterile-labeled OTC IPA prep pads were made by a process adequate to render them sterile, did not test finished batches for IPA identity and strength before release, and did not test incoming components for identity and hazardous impurities.

What FDA found

  1. The quality control unit did not ensure that OTC IPA prep pads labeled sterile were made by a process shown to render them sterile.

    21 CFR 211.22
  2. The firm did not test each finished batch for identity and strength of the active ingredient IPA before release.

    21 CFR 211.165(a)
  3. The firm did not test incoming glycerin, propylene glycol, ethanol, and IPA for identity and hazardous impurities such as DEG/EG or methanol as required.

    21 CFR 211.84(d)(1)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with actions taken and steps to prevent recurrence; it also recommends a qualified CGMP consultant and a six-system audit.

Who should pay attention

  • brands that buy OTC drug products from this contract manufacturer
  • distributors and importers of sterile-labeled prep pads
  • drugmakers using glycerin, propylene glycol, ethanol, or IPA components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk